Press Releases

Press Releases

Date	Title
Apr 07, 2024	Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Mar 20, 2024	Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Mar 13, 2024	Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Mar 05, 2024	Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Feb 27, 2024	Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Feb 15, 2024	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Jan 29, 2024	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Jan 09, 2024	Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
Jan 07, 2024	Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
Jan 02, 2024	Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference

For Media Inquiries, please contact:

Christine Lindenboom

SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276

MEDIA KIT

Essential assets and documents related to Alnylam

Looking for specific information that isn't listed above?